Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LION: lifting immune checkpoints with NSAIDs
ISRCTN73037722Phase 2Recruiting
- Sponsor
- The Christie
- Start
- May 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 2, open-label trial of celecoxib in triple-negative breast cancer (TNBC), non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC) (3 cohorts), sponsored by The Christie. Primary endpoint: Best overall response rate. Started May 2024; status: recruiting.
02
Drugs
celecoxib
03
Conditions
triple-negative breast cancer (TNBC)non-small cell lung cancer (NSCLC)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on ISRCTN73037722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN73037722.